At have an average energy of 6.8 MeV and their range in soft tissue is only 55-80 µm, i.e. a few cell diameters. Because of the low range of the α-radiation in tissues, need for patient shielding is greatly reduced, allowing α-radioimmunotherapy to be given on an outpatient basis (Larsen et al, 1999) . Moreover, the high LET (linear energy transfer) of 211 At, about 97 keV µm -1 , is close to the optimum value for high RBE (relative biological effectiveness) (Brown, 1986) . Alpha emitters are also generally associated with low oxygen enhancement ratio and virtual absence of dose-rate effects (Barendsen et al, 1965; Hall, 1994) . The short range of the α-emitters implies that the radiation dose is delivered to the cell or within its close vicinity. This fact, together with the targeting ability of the MoAb, makes α-particle-emitting immunoconjugates attractive for radioimmunotherapy against dispersed cells and micrometastases.
The present study was performed to explore the ability of 211 At-rituximab to selectively inactivate NHL tumour cells with acceptable bone marrow damage.
MATERIALS AND METHODS

Haematopoietic cells and lymphoma cell lines
Fresh mononuclear bone marrow (BM) cells from healthy volunteers were used. BM may contain various amounts of B-lymphocytes (CD20 + ), from < 1% up to 15-20%. Peripheral blood progenitor cells (PBPC) were harvested in the recovery phase following chemotherapy and G-CSF (in patients with other diagnoses than NHL), and enriched CD34 + haematopoietic cells (from PBPC) were used. Two B-cell NHL cell lines in exponential growth, RAEL (high-grade) and K422 (low-grade) (Dyer et al, 1990) , expressing the CD20 antigen, were studied.
Monoclonal antibody
A chimaeric anti-CD20 MoAb with murine variable regions and human IgG 1 -kappa constant regions, IDEC-C2B8 or rituximab, was used. This MoAb is marketed by IDEC Pharmaceutical Corporation, San Diego CA and by Genentech Inc, San Francisco CA in the USA under the name of Rituxan®, and in Europe by Hoffmann-La Roche Ltd, Basel, Switzerland under the name MabThera™. The CD20 antigen is expressed at high density on malignant B-cells as well as normal B-lymphocytes, but not on early B-cells and stem cells. Within the time-frame of 211 At decay, the CD20 antigen is virtually stable on the cell surfaces (Reff et al, 1994) .
Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate 211 At-rituximab against non-HodgkinÕs lymphoma cells
Radionuclides and labelling
Astatine-211 was produced in a cyclotron at the Department of Physics, University of Oslo (Larsen et al, 1994 a) At and 125 I and purified as previously described for other proteins (Larsen et al, 1994 b) . The resulting radioimmunoconjugates,
211
At-rituximab and 125 Irituximab, were sterile-filtered prior to the biological experiments, using a Millex-GV 0.22 µm filter (Millipore, Bedford MA, USA).
In the present experiments the specific activity varied from 10-75 MBq mg -1
. The specific binding fraction of 211 At-labelled rituximab was determined in a one-point assay. Cell-bound radioimmunoconjugate was measured in triplicate after incubation at room temperature for 1-2 h, using approximately 10 7 cells in 0.3 ml medium. An average of 36.4% of the labelled antibody (range 17.3-54.1%) bound to antigen-positive RAEL cells, whereas non-specific binding of ≤ 1.8% was measured on the antigen-negative osteosarcoma cell line OHS. A binding fraction of 36% in the one-point assay corresponds to an immunoreactive fraction at infinite antigen excess (Lindmo et al, 1984) of about 50-60%, as verified experimentally (data not shown).
Cell killing activity of 211 At-rituximab
Different amounts of 211
At-rituximab were added to a fixed concentration of 10 6 cells ml -1 . Initial radioactivity concentrations (kBq ml -1 ) in the test tubes were counted in a LKB Wallac 1277 Gammamaster gammacounter (Wallac Oy, Turku, Finland). Two experimental series with different incubation time were performed: A 1 h incubation series to study the efficacy of cellbound radioimmunoconjugate; and a 4 h incubation series to simulate the prolonged circulation in vivo of IgG-type radioimmunoconjugates. Four hours are similar to the effective half-life of the radiopharmaceutical in the body, as indicated in mice experiments. After the incubation, under soft stirring for 1 or 4 h, the cells were washed in culture medium and centrifuged three times. Then survival was measured in clonogenic assays, and compared to that observed in the absence of radioactivity.
The number of clonogenic tumour cells remaining after exposure to 211 At-rituximab was assessed by a modified version (Kvalheim et al, 1987) of the Courtenay and Mills soft agar clonogenic assay (Courtenay and Mills, 1978) . For evaluation of toxicity on haematopoietic cells the CFU-c (colony forming unit cell) assay with METHOCULT H4433 medium (Stem Cell Technologies Inc, Vancouver, Canada) was used. The toxicity of the labelled MoAbs was also tested on more primitive (stem cellnear) haematopoietic cells, using the LTC-IC (long-term culture initiating cell) assay (Eaves et al, 1991) . Briefly, the cells were seeded on a pre-irradiated (20 Gy) human bone marrow stroma mono-layer in the medium MYELOCULT H5100 (Stem Cell Technologies Inc), supplemented with 50 µM hydrocortisone, and cultured for 5 weeks before secondary culture in CFU-c assay.
Therapeutic gain
The relationship between the initial concentration of radioactivity (kBq ml -1 ) and clonogenic survival was, in the range tested, best fitted by quadratic regression. The concentration of 211 At-rituximab giving a survival of 10% or 37% (A 10 or A 37 ) was calculated from the survival curves. A therapeutic gain factor (TGF) for tumour cells relative to haematopoietic cells exposed to At-labelled rituximab in 100 µl were co-injected into the tail vein of each animal. Approximately 4 µg rituximab were injected per mouse. At various time-points three mice were sacrificed, the organs were dissected out and weighed, the radioactivity contents were measured and the percentage of injected dose per g of tissue was determined.
Statistical analyses and curve estimations
SPSS 8.0, EXCEL 97 for Windows, and SigmaPlot (Scientific Graphic Software, version 2, Jandel Corporation) were used in the statistical analyses, plots and graphs. The input values for the survival curves were calculated by the mean log 10 anti-log of surviving fractions for separate doses in the individual experiments (presented in the Figures). Survival curves were fitted to the data using quadratic regression of log 10 survival. The 95% confidence intervals (CI) of the survival curves were calculated using log 10 of the 95% CI from each point on the survival curves.
RESULTS
Cell-bound radioactivity
Cell-bound radioactivity (mBq cell -1 ), measured after 1 h incubation, is presented in Figure 1A for normal BM and CD34 + cells and in Figure 1B for the RAEL cells. It is seen that, as expected, much more radioactivity was bound to the tumour cells than to the normal BM cells. Table 1 the values are given with 95% CI.
BM cells tested in LTC-IC were separated from cells in standard CFU-c assay just before plating. Hence, these stem cells were exposed to the same crossfire irradiation from B-cells in the pellets before seeding. The experiments showed a tendency of higher toxicity on BM evaluated in LTC-IC as compared to CFU-c assay, but the differences were not significant, P = 0.36 (paired samples t-test, two-tailed). In contrast, the toxicity towards CD34 + cells was lower for the tested initial concentrations of activity ( Figure 2A ).
In Figure 2C and 2D the results of 4 h measurements are shown. Since 4 h incubation may reflect a more realistic time schedule with regard to the effective half-life of 211 At-rituximab administered to patients, the study was extended with these series. The data in Figure 2C and 2D represent three individual experiments for each tumour cell line, BM from three different donors and two PBPC products. Again the 211 At-rituximab was found to be far more toxic to the tumour cells than to the haematopoietic cells. However, neither between BM and PBPC nor between the two tumour cell lines were significant differences found. Calculations from the survival curve parameters give the following mean A 10 values (kBq ml -1 ): 22.8 for BM, 5.6 for RAEL and 4.3 for K422. Such low survival level was not observed for PBPC in the given range of initial activity concentrations. At an initial activity concentration of 25 kBq ml -1 , the mean log cell kills were 1.01 for BM CFU-c , 0.61 for PBPC CFU-c , 3.39 and 3.54 for RAEL and K422, respectively (Table 1) .
The amounts of radioactivity added in this study correspond to a rituximab concentration of less than 8 µg ml -1 . In a control experiment with unlabelled rituximab at similar concentrations as used with the radioimmunoconjugate, no significant effect on survival, neither of the RAEL nor the BM cells, was observed (data not shown). This indicates that the radioisotope was essential for the effectiveness of 211 At-rituximab in the present experiments. The concentrations used represent less than 3.5% of the serum concentration obtained in clinical trails using therapeutic doses of native rituximab (McLaughlin et al, 1998) .
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Therapeutic gain
Both 1 h and 4 h incubation with 211 At-rituximab gave favourable therapeutic windows between tumour cells and haematopoietic cells. The average TGF 37 ± SD, is presented in Table 2 . In the 1 h series TGF 37 between RAEL and BM CFU-c was 5.2 in average. TGF 37 for tumour cells vs BM CFU-c in the 4 h series were 2.3 for RAEL and 3.0 for K422. Table 3 presents the tissue distribution of   211 At-rituximab and 125 Irituximab in eight organs of the mice, within a time-frame of 1-23.5 h. The biodistribution of 211 At-rituximab was similar compared to that of 125 I-rituximab, and revealed the general characteristics of IgG radiolabelled MoAbs, i.e. high initial activity levels in blood and blood-rich tissues.
Biodistribution in mice
DISCUSSION
The reported experiments were designed to assess targeted α-emitter exposure to dispersed B-lymphoma cells and haematopoietic progenitor cells.
The normal bone marrow cells generally showed a low sensitivity following exposure to 211 At-rituximab. BM contains various amounts of B-lymphocytes, ranging from < 1% up to 20%, which may explain the considerable variation in cell-bound activity observed in different experiments. The difference in toxicity on the BM cells, reflected in the survival curve (Figures 2A and 2C) , could possibly be explained by crossfire irradiation of the antigennegative clonogenic cells from B-cells in the pellets before seeding. This is further supported by the very low toxicity observed with CD34 + -enriched cells, which had low binding of 211 At-rituximab, due to the virtual absence of B-cells in this cell population. Furthermore, PBPC products, which contain about 0.5-1% B-cells, also showed a trend towards lower cytotoxicity from the radioimmunoconjugate compared to BM, although the difference was not statistically significant. Neither was the survival significantly different between BM cells tested concurrently in the CFU-c and the LTC-IC assay.
Astatine-211-labelled rituximab was highly cytotoxic to both high-and low-grade NHL cells when measured after 4 h incubation, and no significant difference in survival between the two cell lines was found ( Figure 2D ).
In our experiments, A 37 following 1 h incubation was 3.8 and 19.5 kBq ml -1 for RAEL and BM CFU-c , respectively, whereas the calculated value for CD34
+ cells was as high as 100.9 kBq ml -1 . Hence, A 37 for CD34 + cells was almost identical to the values previously reported for human cell lines exposed to non-specific 211 At-BSA (bovine serum albumin) (Larsen et al, 1994a) . The biodistribution profile indicated that the quality of the immunoconjugate had not been significantly reduced by labelling with 211 At and also that the stability of the conjugate in vivo was adequate. As with 131 l-labeled compounds a blocking agent should be used for therapeutic purposes to minimize radiation dose to the thyroid for 211 At (Larsen et al, 1998) . The current study confirms previous reports indicating that α-emitting immunoconjugates may have selective anti-tumour effect. One study by Harrison and Royle (1987) used 211 At conjugated to a T-cell antibody (OX7) to treat a T-cell lymphoma in mice and increased the median survival time of mice and probably 'cured' more than half of the animals (Harrison and Royle, 1987) . Later Behr and colleagues (1999) compared the therapeutic efficacy and toxicity of the α-emitter 213 Bi with that of the β-emitter 90 Y, linked to a monovalent Fab′ fragment, in a human colonic cancer xenograft model in nude mice (Behr et al, 1999) . They concluded that radioimmunotherapy with α-emitters may be therapeutically more effective than conventional β-emitters. Recently pharmacokinetics and dosimetry of a 213 Bi-labelled anti-CD33-antibody in patients with leukaemia was reported (Sgouros et al, 1999 Mean ± SD Table 3 Biodistribution a of strongly reduce HAMA (human anti-mouse antibody) responses in patients. However, the prolonged biological half-life of the humanized MoAbs could cause problems with increased radiation dose to normal tissues, and hence a decreased therapeutic index, when isotopes with longer half-life (days) are utilized (Bruland, 1995; Multani and Grossbard, 1999) . The use of a relatively shortlived isotope like 211
At will make those differences in biological half-life less relevant.
As pointed out,
211
At also has several advantages from a radiation-protection point of view. More than 99% of its radiation energy is from α-particles. The short half-life (7.2 h) could reduce the hospitalization time, and the short tissue-range of the α-particles (maximum 80 µm) would simplify the protection of the staff and environment (Larsen et al, 1999) .
A BM progenitor cell survival of 5% should be sufficient for recovery without stem-cell support. This survival level of BM CFU-c was observed at an initial activity concentration of 70.3 kBq ml -1 following 1 h incubation. The corresponding log cell kill of RAEL was as high as 4.8. Consequently there may be a significant therapeutic window if non-myeloablative doses of 211 At-rituximab are explored clinically.
In conclusion, our study shows that rituximab labelled with 211 At exerts selective cytotoxicity to NHL tumour cells in vitro. The effect of the radioimmunoconjugate will now be investigated in patients with relapsed B-cell lymphomas.
